119 results about "Herpes simplex virus DNA" patented technology

The present invention relates to methods and compositions for treating and / or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. In particular, provided are long-acting injectable depot pharmaceutical compositions comprising Compound 1 or a pharmaceutically acceptable salt thereof; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament and for the treatment of diseases or disorders caused by, or associated with, herpes virus.

The invention relates to the technical field related to immunological detection, in particular to a mouse anti-porcine herpesvirus type 1 gE monoclonal antibody as well as an immunogen and application of the mouse anti-porcine herpesvirus type 1 gE monoclonal antibody. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: GFSLSTSGMG, IVWGSETGRVTISRDNSK and VRYYDGDDD, and the amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: KSSQSLLYSDGKTFLN, LGSNRAS and SSLPHED. The monoclonal antibody can be specifically combined with gE proteins of all subtypes of the porcine herpesvirus type 1, and a porcine herpesvirus type 1 detection kit prepared from the monoclonal antibody has the advantages of high sensitivity, strong specificity, wide detection range, short detection time and the like.

The invention discloses a cat kidney suspension culture cell line suitable for serum-free suspension culture and application of the cat kidney suspension culture cell line. The name of the cell line is F81-B4, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.46350. After 50 generations of continuous subculture, the cells still can maintain the original proliferation level and cellular morphology, the cell number can reach 9.0 * 10 < 6 > / mL after the cells are subcultured at the density of 1.0 * 10 < 6 > / mL for three days, the multiplication time is 22-26 hours, and the cell proliferation speed is equivalent to that in a shake flask when the cells are amplified to a 10L bioreactor for culture. The cell line is highly susceptible to feline parvovirus, feline calicivirus, feline herpes virus, canine parvovirus and canine distemper virus, the virus content of a virus solution harvested 72 h after FPV virus inoculation can reach 107.5 TCID50 / mL, the virus content of a virus solution harvested 24 h after FCV virus inoculation can reach 1010.8 TCID50 / mL, the virus content of a virus solution harvested 48 h after FHV-1 virus inoculation can reach 107.5 TCID50 / mL, compared with an existing F81 adherent cell production process, the production process has the advantages that the production efficiency is high, and the production cost is low. The method has the characteristics of rapid lesion, short virus collection time and high titer. The cell matrix is an ideal cell matrix which can be used for culturing the three viruses.

The invention belongs to the field of biological medicine, and particularly relates to an artificially synthesized polypeptide P2 and application thereof in resisting herpes virus infection. According to the invention, a polypeptide P2 of key amino acid residues (77N, 80I, 82N, 84N, 85N and 129F) combined with virus glycoprotein gD in a specific targeting host cell surface receptor Nectin-1 is designed and obtained through an RFdiffusion algorithm; the polypeptide P2 can significantly inhibit PRV infection, and has no significant cytotoxicity; the polypeptide P2 can be used for remarkably down-regulating PRV UL42 protein expression and gB mRNA (messenger Ribonucleic Acid) level; based on the conservative property of Nectin-1 in a herpes virus invasion mechanism, the polypeptide P2 can also be used for inhibiting infection of other herpes viruses (such as HSV-1 and HSV-2), and an important strategy is provided for developing novel anti-herpes virus drugs.

The present disclosure provides compounds of Formula I-V that are useful for inhibiting a viral disease in a subject. In some embodiments, the compounds of Formula I-V may be used to inhibit herpes virus.

The invention discloses a monoclonal antibody of feline herpesvirus gB protein, an antigen epitope peptide recognized by the monoclonal antibody and application of the monoclonal antibody. The monoclonal antibody of the feline herpesvirus gB protein comprises an antibody heavy chain and an antibody light chain, wherein a variable region of the antibody light chain comprises a CDR1 consisting of an amino acid sequence as shown in SEQ ID NO.1, a CDR2 of which the amino acid sequence is QVS and a CDR3 consisting of an amino acid sequence as shown in SEQ ID NO.3; a variable region of the antibody heavy chain comprises a CDR1 composed of an amino acid sequence shown in SEQ ID NO.4, a CDR2 composed of an amino acid sequence shown in SEQ ID NO.2 and a CDR3 composed of an amino acid sequence shown in SEQ ID NO.5. According to the research, one specific monoclonal antibody is successfully prepared and obtained, the antigen epitope recognized by the specific monoclonal antibody is identified, and a biological foundation is laid for developing a specific detection reagent of FHV-1.

The invention discloses a self-aggregation-induced emission type photosensitizer and a preparation method and application thereof. The photosensitizer has excellent AIE performance, and singlet oxygen can be efficiently generated after aggregation in a physiological environment; and the photosensitizer can effectively overcome the aggregation-induced quenching phenomenon, and has a synergistic effect with the lovir drugs, so that the anti-herpes virus activity is remarkably improved, and the dosage and side effects are reduced.

The present invention relates i.a. to a method for treating or preventing avian influenza virus infections in turkeys comprising administering an effective amount of a rHVT-H5HA COBRA.

A patch composition for targeting herpes virus comprising the following ingredients: a patch base, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, peppermint, sodium saccharin, naringin, wind wheel grass extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethyl cellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, strontium chloride hexahydrate, tranexamic acid, two-faced needle extract, sodium monofluorophosphate, sea salt, potassium nitrate, sodium chloride, and purified water q.s.

The invention discloses a visual detection reagent for koi herpesvirus. The visual detection reagent comprises a lower phase MIRA amplification system and an upper phase CRISPR / Cas12a detection system which are arranged in the same reaction tube. The method has no high professional requirement on detection personnel, is low in equipment requirement, short in detection time and high in sensitivity, has extremely high specificity and simplicity and is convenient to popularize and apply, and the final detection result can be directly observed by naked eyes.

The present invention provides recombinant herpes virus of turkeys (HVT) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.

The present application relates to an avian cell line capable of supporting viral growth of Marek's Disease Virus (MDV), including Herpes Virus of Turkeys (HVT), methods of producing such cell lines, and therapeutic uses of the cell lines and resulting vaccines.

The invention relates to the technical field of pathogen detection, in particular to a primer probe group for detecting herpes virus type 1-8 as well as a freeze-drying agent and application of the primer probe group. The primer probe group provided by the invention can be used for performing multiplex PCR detection on the herpes virus type 1-8, has good reagent specificity, has no nonspecific cross reaction with pathogens except the herpes virus type 1-8, has high sensitivity, has the lowest detection limit of 200 copies / mL, and provides a timely, effective, simple and convenient auxiliary detection tool for clinical detection. Furthermore, a freeze-drying agent containing the primer probe group provided by the technical scheme is good in stability, can be stored at normal temperature (1 year) and transported, has intra-group and inter-group variation coefficients of less than 3% when being used for simultaneously detecting the herpes virus type 1-8, is good in repeatability, is a stable, efficient and simple herpes virus type 1-8 detection reagent, and has wide application prospects. The clinical application is convenient.

Provided are use of a bioactive protein in the preparation of a drug for treating herpes virus infection and a pharmaceutical composition for treating herpes virus infection. The pharmaceutical composition mainly comprises a bioactive protein, a matrix, a humectant, a pH regulator, and a preservative. The present invention has the following technical effects: 1) By means of a large amount of research and experimental verification, the inventors have discovered for the first time that anhydridized lactoferrin, a modified bioactive protein, has an inhibitory effect on herpes zoster virus (VZV). 2) In the pharmaceutical composition, the type and amount of excipient and the proportion of the main ingredient are reasonable. The pharmaceutical composition is administered in ointment form, in spray form, or in other dosage forms suitable for external use, has a significant therapeutic effect, has small local toxic side effects, has very low acute dermal toxicity, causes no irritation or allergy, does not interfere with normal skin functions, and is safe and effective.

The present invention provides a new silicone gel composition suitable for preparing an anti-herpes viruses product of natural origin. The new composition is capable of permeating at the target epidermis side of the skin. The new composition is capable of retaining in the target epidermis side of the skin for a certain period. The present invention also relates to the topical use of the silicone gel composition for the treatment of viruses of the herpes family at a posology regime.

The invention discloses an application of a natural anthocyanin substance in preparation of an antiviral drug, which is characterized in that anthocyanin is used as a potential effective component for inhibiting the activity of herpes virus DNA polymerase, and the activity of the DNA polymerase is inhibited through the combination of the anthocyanin and the DNA polymerase, so that a good anti-herpes virus effect is realized.

The invention discloses a method for killing bovine herpesvirus by sodium chloride aerosol. The method comprises the following steps: (1) preparing sodium chloride aerosol of which the average particle size is 800nm and the particle size distribution is between 500nm and 8mu m, in the specific preparation process, respectively introducing a saturated sodium chloride aqueous solution and absolute ethyl alcohol into dry airflow of a spray dryer according to a volume ratio of 1: 1, and drying by the spray dryer to prepare the sodium chloride aerosol; and (2) the prepared sodium chloride aerosol is used as a bovine herpes virus killing agent to kill bovine herpes viruses, and in the virus killing process, the dosage is 10-60 mg, and the killing time is 10-30 s. The sodium chloride aerosol has the advantages that the sodium chloride aerosol has special antivirus efficacy in a specific dosage and time range, a high-concentration sodium chloride solution can dehydrate bacterial cells and destroy cell membrane structures of the bacterial cells through osmotic pressure difference to cause growth inhibition or death of bacteria, and especially 100% of bovine herpes viruses (BHV-1) can be killed in a very short time with a small dosage of sodium chloride aerosol.

The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The invention provides application of 7, 8-dihydroxyflavone in preparation of a medicine for treating diseases caused by herpes virus infection, and belongs to the technical field of biological medicine. The 7, 8-dihydroxy flavone can be used for remarkably inhibiting infection of herpes simplex viruses HSV-1 and HSV-2, and has broad-spectrum anti-HSV activity. According to the present invention, the HSV virus protein expression can be significantly inhibited by pretreating the virus with the 1, 7, 8-dihydroxyflavone and treating the cells after the virus adsorption, the virus plaque formation can be reduced, and the dose dependence can be provided; experiments show that the 7, 8-dihydroxyflavone plays the anti-herpes simplex virus activity mainly through targeting host protein fructose-diphosphate aldolase A. The 7, 8-dihydroxyflavone has the anti-herpes simplex virus activity. Mouse in-vivo experiments prove that the 7, 8-dihydroxyflavone can significantly improve the survival rate of HSV-1 mice, improve the weight reduction trend and reduce the virus titer of lung tissues; meanwhile, mouse genital organ lesions caused by HSV-2 infection can be remarkably relieved, and the weight of infected mice is improved. Therefore, the compound 7, 8-dihydroxyflavone is expected to be developed into a candidate drug for treating the herpes simplex virus.

The invention relates to a loop-mediated isothermal amplification method for rapid inspection and quarantine of horse herpes viruses 1 and 4 of imported racing horses. The loop-mediated isothermal amplification method comprises the following steps: S1, obtaining a biological sample of the imported racing horses; s2, extracting a nucleic acid template from the biological sample; s3, mixing the nucleic acid template with a reaction system containing nucleic acid polymerase and a specific loop-mediated isothermal amplification primer group aiming at the equine herpes virus type 1 or type 4; s4, performing a nucleic acid amplification reaction under a constant temperature condition; and S5, detecting an amplification product, and judging whether the imported racing horse is infected with the horse herpes virus type 1 or type 4 or not. The loop-mediated isothermal amplification method for rapid inspection and quarantine of the imported racing horse herpes viruses type 1 and type 4 can effectively meet the requirements of rapid customs clearance and epidemic disease prevention and control of imported racing horses.

The invention relates to a preparation method of an antiviral drug Priteelivir. According to the preparation method, a cheap commercial raw material compound shown in a formula 1 is adopted, a compound shown in a formula 3 is synthesized by utilizing acrylonitrile to form a heterocyclic ring, an ester group is hydrolyzed in an alkaline environment to obtain a compound shown in a formula 4, and then the compound shown in the formula 4 and a compound shown in a formula 5 are subjected to an amidation reaction to synthesize the target product Priteelivir. The method has the advantages of simplicity in operation, mild reaction conditions, high yield and simplicity and convenience in post-treatment, and is suitable for industrial batch production.

The invention relates to a novel thiazole compound as shown in a formula I and pharmaceutically acceptable salts thereof, or solvates or hydrates thereof, and also relates to a pharmaceutical composition containing the compound, a method for preparing the compound, and application of the compound in preparation of medicines for preventing and / or treating diseases caused by herpes viruses.

The invention discloses a herpes zoster treatment laser device with a function of protecting tissues outside a target area, and belongs to the technical field of herpes zoster laser treatment equipment.The herpes zoster treatment laser device comprises a fixed base, a lifting assembly, a laser treatment device and an area limiting assembly, and the area limiting assembly is arranged on the lifting assembly; the device is used for constraining a laser beam of the laser treatment device in a herpes zoster area. According to the invention, the laser beam of the laser therapeutic apparatus is restrained in the herpes zoster region through the region limiting assembly, so that the laser energy of the laser therapeutic apparatus is accurately focused on the diseased region of the herpes zoster in the treatment process, thereby avoiding the situation that the laser irradiation range is too large or deviates from the core region of a focus, and improving the treatment efficiency. Therefore, the action effect of laser on herpes viruses and damaged tissues is improved, innocent tiredness of part of normal tissues is avoided, and the rehabilitation process of a patient is guaranteed.

The invention relates to the technical field of biological viruses, and particularly discloses an efficient cat herpesvirus purification process which comprises the following steps: 1) clarifying virus harvesting liquid; and 2) concentrating, washing and filtering the clarified liquid by using a hollow fiber column. And the virus content of the final sample is not obviously lost, the total protein can be reduced to be less than 80 mu g / ml, and the turbidity is as low as 20.3 NTU. As the cat herpes virus has the characteristics of temperature sensitivity, poor shear force tolerance, similar virions and impure proteins in size, incapability of removing impure proteins through a filtering method and the like, a great challenge is brought to a downstream purification process, and the method provides an efficient cat herpes disease purification process; the method greatly reduces the antigen loss, has the characteristics of low production cost, excellent purification effect and the like, avoids the use of multi-step purification steps such as a chromatographic process, and enables the purification process to be simpler and more efficient.

The present invention discloses an application of icariin I or a pharmaceutical salt thereof in the preparation of an antiviral drug. The virus refers to Kaposi's sarcoma-associated herpes virus. The drug small molecule icariin I screened from a natural product library can significantly inhibit the lytic replication of KSHV, and the present invention provides a new solution for the treatment of KSHV.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The present invention belongs to the field of monoclonal antibodies and biological detection technology, and specifically relates to a hybridoma cell line that secretes anti-eel herpes virus (AngHV) monoclonal antibodies, anti-eel herpes virus monoclonal antibodies, and applications thereof. The anti-eel herpes virus monoclonal antibodies of the present invention are prepared using purified eel herpes virus particles as antigens and are capable of specifically identifying eel herpes virus. A double-antibody sandwich ELISA detection kit has been developed based on the anti-eel herpes virus monoclonal antibodies. The kit is prepared using anti-eel herpes virus monoclonal antibodies as capture antibodies and eel herpes virus polyclonal antibodies as detection antibodies. The kit is suitable for the detection of eel herpes virus, has good specificity and sensitivity, and the method is simple and rapid, with broad application prospects.

Disclosed herein include methods and compositions for pig-to-human organ xenotransplantation using genetically modified pigs with triple-gene knockouts and human gene insertions. In some embodiments, the organ xenotransplantation is a pig-to-human kidney xenotransplantation demonstrating the restoration of renal function. Also disclosed are methods and compositions for preventing acute rejection and / or reactivation of porcine herpesvirus, which contributes to advancing xenotransplantation as a viable solution to the global organ shortage.

The present disclosure relates to a method of increasing genetic stability of a viral vector carrying a heterologous nucleic acid, said method comprising inhibiting transcription and / or translation of said heterologous nucleic acid, said viral vector being an adenoviral (AV) vector, a poxvirus vector, a baculovirus vector, or a herpes virus vector, wherein said increasing is as compared to the absence of said inhibiting. Furthermore, provided are cells which are useful for producing viral vectors.